Understanding Dermatology Practice Sales Trends Ahead
TUSK Practice Sales unpacks the valuation landscape, buyer dynamics, and strategic window for dermatology practice owners.
For dermatology practice owners considering a sale, the current moment represents one of the most favorable environments the market has seen. High buyer demand, compressed competition, and access to institutional capital are converging, creating what many are calling a "golden age" for dermatology mergers and acquisitions (M&A).
TUSK Practice Sales, a leading broker specializing in dermatology practice transactions, breaks down the trends, timelines, and important factors that today's dermatology owners need to understand before entering the marketplace.
According to Kevin Cumbus, Founder and President of TUSK Practice Sales, "We're seeing dermatology valuations that rival those in more mature sectors like dental. The uniqueness of this moment lies in the second wave of the dermatology consolidation cycle, where increased private equity investments drive competition, aggressive bidding, and favorable deal structures for sellers with prime assets."
The Transformation of Dermatology M&A
Although dermatology is relatively newer to the consolidation cycle compared to other healthcare sectors, its evolution follows a well-established trajectory. Over the past two decades, private equity and management service organizations (MSOs) have reshaped ownership landscapes across various specialties—including dental, physical therapy, and veterinary medicine. Now, dermatology is undergoing a similar transformative shift, presenting notable opportunities for those looking to sell their practices.
As foundational platforms form and scale, sellers can position themselves advantageously when their partner seeks to recapitalize, as this often leads to substantial additional benefits. However, it’s crucial that sellers negotiate their equity rights effectively and align with the right strategic partner from the outset.
Ryan Mingus, Managing Director and Partner at TUSK, shares insights: "We've negotiated advantageous equity positions for our clients that balance potential high returns with protective measures against downside risks. Yet, it remains essential for sellers to conduct thorough due diligence on prospective partners to ensure they are signing on with a healthy business. This underscores the importance of a trusted broker in navigating these waters."
Who Are the Buyers in 2025?
The dermatology M&A landscape is now significantly influenced by two primary buyer profiles, each possessing unique motivations and implications for practice owners:
1. Private Equity Groups Seeking Initial Platforms
These investor groups actively seek to acquire a well-established dermatology practice, which can serve as a foundational platform for a larger MSO. Such platform deals often command the highest valuations and most favorable deal structures, setting the stage for lucrative longer-term plans.
Ryan Mingus emphasizes, "Platform deals represent the crown jewel of healthcare M&A. For dermatology practice owners with the right attributes, leading a new platform can be a pivotal career opportunity."
2. PE-Backed MSOs in Expansion Mode
Once a platform is in place, sponsors typically pursue growth through additional acquisitions, integrating new practices into a cohesive operational framework. These MSOs are often quick, financially robust, and offer attractive deals for practitioners aligned with their clinical and cultural vision. For sellers, this offers a streamlined route to liquidity while maintaining clinical independence.
3. Doctor-to-Doctor Sales
While institutional buyers capture much attention, transactions between physicians remain active, particularly among smaller practices with revenues under $2 million. These deals can simplify transitions but usually offer less competitive dynamics compared to private equity transactions.
"Understanding which buyer segment your practice fits is essential," advises Kevin Cumbus. "Not every practice qualifies for platform partnerships, but every owner deserves clarity on their position and how to optimize outcomes."
Key Trends in Dermatology M&A for 2025
Valuations at Historic Highs
Leading practices are frequently selling at impressive multiples of EBITDA, ranging from 5 to 10 times, with considerations like cash at closing, retained equity, and favorable employment conditions based on specific practice dynamics. Practices that offer multiple providers, generate cosmetic revenue, and maintain clear financials are attracting the best offers.
Competitive Tension Benefits Sellers
With fewer large platforms compared to other healthcare sectors, dermatology deals often involve multiple offers, empowering sellers to negotiate not just the price, but also the terms, timeline, and cultural fit. Engaging with an experienced broker familiar with key players can significantly further these objectives.
Younger Sellers with Strategic Goals
More practice owners in their 40s and 50s are engaging in deals to relieve operational pressures, spur growth, or partially cash out while still leading their practices under broader management.
Upsides From Second Bites of the Apple
Sellers maintaining equity in initial sales may reap additional rewards upon platform recapitalization. However, it’s vital for this equity to be structured in a protective manner to ensure it translates into real value.
Potential Disruptions to the Current Market
Despite this favorable landscape, multiple macroeconomic and policy variables could alter M&A dynamics going forward:
Interest Rate Fluctuations
As borrowing costs change, buyer leverage and enthusiasm may lessen.
Possible Capital Gains Tax Adjustments
Potential alterations in capital gains tax regulations could increase seller tax liabilities, lowering net profits from transactions.
Shifts in Political Landscape
Changes in healthcare policies or intensified scrutiny on private equity could introduce new challenges for potential buyers.
Economic Trends
A downturn in the economy could impact buyer confidence and access to necessary capital.
"Exploring options during a competitive market with available capital is essential," concludes Kevin Cumbus. "It's not just about immediate sales—understanding your situation, safeguarding your interests, and planning thoughtfully are key."
About TUSK Practice Sales
TUSK Practice Sales provides M&A advisory services within the healthcare arena. The firm has successfully completed numerous transactions, exceeding $1 billion across various specialties. Leveraging deep market insights and access to an extensive network of buyers, TUSK assists clients in pursuing M&A that maximizes their long-term value. With a combined experience exceeding 50 years in practice transitions, we deliver tailored solutions that align with our clients' strategic and financial goals.
Frequently Asked Questions
What is driving the increase in dermatology practice sales?
High buyer demand, low competition, and access to capital are key factors fueling increased sales.
What can sellers expect in terms of valuations?
Valuations are currently at historic highs, often achieving multiples from 5 to 10 times EBITDA.
Who are the main buyers in dermatology M&A?
The primary buyers include private equity groups and PE-backed MSOs, along with individual doctor-to-doctor transactions.
What are platform deals in dermatology?
Platform deals are acquisitions of established practices that serve as foundational bases for further business expansions.
What potential risks could impact the current favorable market?
Interest rate changes, potential tax law adjustments, and economic downturns could all affect the M&A dynamics in the dermatology space.
